Is cabergoline mystical in euprolactemic polycystic ovarian syndrome
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20253096Keywords:
Cabergoline, Euprolactinemic PCOS, LetrozoleAbstract
Background: Polycystic ovarian syndrome (PCOS) is most common in reproductive age females. Cabergoline is a potent long-acting dopamine agonist play an important role in decreasing high prolactin secretion which is present in 30–40% of PCOS and induce ovulation in those with normal prolactin level also. This is attributed to reduction of an occult hyperprolactinemia in PCOS patients.
Methods: This is a randomized, prospective, controlled study includes 100 Euprolactinemic infertile PCOS, 50 in each group, Group A (letrozole cabergoline group) patients received tablet letrozole 5 mg/day in 2 divided doses 2.5 mg from cycle day 3 to day 7 plus cabergoline tablet 0.25 mg, half tablet twice weekly for 4 weeks starting from cycle day 3 with letrozole despite normal serum prolactin level. Group B (letrozole Group):patients received only letrozole same as group A. Primary outcomes-ovulation rate, number of dominant follicles and secondary outcomes-pregnancy, miscarriage, multiple pregnancies, OHSS, side-effects of cabergoline were studied. Statistical analysis was done.
Results: Study groups compared for the demographic characters, basic clinical data, duration and type of infertility which showed no significant difference. Statistically significant difference in group A ovulation rate 76% (p value 0.0124), number of dominant follicles (p value 0.029). Pregnancy rate 72% in group A and 48% in group B (p value 0.014). No statistical difference in miscarriage (p value 0.15), twin pregnancies (p value 0.86), OHSS (p value 1.0) and no side effects.
Conclusions: Addition of cabergoline to Letrozole in induction of ovulation in euprolactinemic infertile PCOS results in increased ovulation, high pregnancy rate compared to use of letrozole alone, with very few side-effects.
Metrics
References
Belosi C, Selvaggi L, Apa R. Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma. Hum Reprod. 2006;21(12):3108–15. DOI: https://doi.org/10.1093/humrep/del306
Harira MM. Efficacy of Cabergoline Combined with Letrozole Versus Letrozole Alone in Anovulatory Pco Women with Europrolactinaemia, Randomized Controlled Trial. Evidence Based Women's Health J. 2025;15(15):1-6. DOI: https://doi.org/10.21608/ebwhj.2024.310047.1344
Witwit SJ. Improving pregnancy rate in infertile patients with polycystic ovarian syndrome receiving clomiphene citrate and cabergoline in euprolactinomic women in single cycle treatment. Ginekologia Polska. 2023;94(6):456-62. DOI: https://doi.org/10.5603/GP.a2022.0070
Rubenfeld ES, Dahan MH. Does the timing of cabergoline administration impact rates of ovarian hyperstimulation syndrome. Obstet Gynecol Sci. 2021;64(4):345-52. DOI: https://doi.org/10.5468/ogs.21067
Garg R, Jain M. Cabergoline for ovarian hyperstimulation: a review of clinical evidence. J South Asian Feder Obst Gynaecol. 2016;7:30-2. DOI: https://doi.org/10.5005/jp-journals-10006-1317
Rasekhjahromi A, Kargarfard S, Kargarfard F, Kalani N. Clomiphene citrate versus cabergoline in ovulation induction by letrozole: a randomized clinical trial study on of infertile polycystic ovary syndrome women. J Med Chem Sci. 2022;5:587-95.
Elbareg AM, Essadi FM. Ovulation Induction in Patients with Polycystic Ovarian Syndrome (PCOS) and Hyperprolactinemia (HPRL): Efficacy of Letrozole (LE) Combined with Cabergoline (CE) in Comparison to (LE) Alone. Med Clin Res. 2021;6(5):535-9. DOI: https://doi.org/10.33140/MCR.06.05.09
ESHRE TR, ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fert Ster. 2004;81(1):19-25. DOI: https://doi.org/10.1016/j.fertnstert.2003.10.004
Butt MS, Saleem J, Aiman S, Zakar R, Sadique I, Fischer F. Serum anti-Müllerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age. BMC Women's Heal. 2022;22(1):199. DOI: https://doi.org/10.1186/s12905-022-01782-2
Cooper TG, Noonan E, Von Eckardstein S, Auger J, Baker HG, Behre HM. World Health Organization reference values for human semen characteristics. Human Reprod. 2010;16(3):231-45. DOI: https://doi.org/10.1093/humupd/dmp048
Zahran KM, Mostafa WA, Abbas AM, Khalifa MA, Sayed GH. Clomiphene citrate plus cabergoline versus clomiphene citrate for induction of ovulation in infertile euprolactinemic patients with polycystic ovary syndrome: A randomized clinical trial. Middle East Fert Soc J. 2018;23(3):173-7. DOI: https://doi.org/10.1016/j.mefs.2017.12.008
Kubota T, Kamada S, Aso T. Combined therapy with bromocriptine and clomiphene citrate for patients with normoprolactinemic amenorrhea. Int J Fert. 1992;37(5):277-82.
Kubota T, Kamada S, Aso T. Combined therapy with bromocriptine and clomiphene citrate for patients with normoprolactinemic amenorrhea. Int J Fert. 1992;37(5):277-82.
Tripathy S, Mohapatra S, Chandrasekhar A. Induction of ovulation with clomiphene citrate versus clomiphene with bromocriptine in PCOS patients with normal prolactin: a comparative study. J Clin Diagnos Res. 2013;7(11):2541. DOI: https://doi.org/10.7860/JCDR/2013/7617.3605
Xue T, Li SW, Wang Y. Effectiveness of bromocriptine monotherapy or combination treatment with clomiphene for infertility in women with galactorrhea and normal prolactin: a systematic review and meta-analysis. Curr Ther Res. 2010;71(4):199-210. DOI: https://doi.org/10.1016/j.curtheres.2010.08.001
Ferrero H, García-Pascual CM, Pellicer N, Simón C, Pellicer A, Gómez R. Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells. Reproduct Biol Endocrinol. 2015;13(1):104. DOI: https://doi.org/10.1186/s12958-015-0102-4
Mohammadbygi R, Yousefi SR, Shahghaybi S, Zandi S, Sharifi K, Gharibi F. Effects of Cabergoline administration on uterine perfusion in women with polycystic ovary syndrome. Pakistan J Med Sci. 2013;29(4):919.
Chen H, Fu J, Huang W. Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history. Cochr Datab Systemat Rev. 2016(7):8883. DOI: https://doi.org/10.1002/14651858.CD008883.pub2
Kilic N, Özdemir Ö, Başar HC, Demircan F, Ekmez F, Yücel O. Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoingin vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna J Med. 2015;5(04):123-7. DOI: https://doi.org/10.4103/2231-0770.165121
Mohammadbygi R, Yousefi SR, Shahghaybi S, Zandi S, Sharifi K, Gharibi F. Effects of Cabergoline administration on uterine perfusion in women with polycystic ovary syndrome. Pakistan J Med Sci. 2013;29(4):919. DOI: https://doi.org/10.12669/pjms.294.3558
Downloads
Published
How to Cite
Issue
Section
